Figures & data
Table 1 Summary of studies examining the efficacy and safety of olmesartan medoxomil plus HCTZ
Table 2 Comparison of demographic and baseline characteristics across studies assessing olmesartan and HCTZ
Figure 1 Change from baseline to end-point in (a) least squares mean (LSM) trough seated diastolic blood pressure (DBP) (b) LSM trough seated systolic blood pressure (SBP) and (c) treatment differences for change from baseline in DBP for dose comparisons: integrated analysis of two factorial studies.
Table 3 Percentage of patients with a treatment response in the combined factorial studies
Table 4 Comparison of 24-hour ABPM values: change from baseline to week 12 – HCTZ add-on study
Figure 2 Mean change in (a) seated diastolic blood pressure (DBP) (mmHg) (b) systolic blood pressure (SBP) (mmHg) from study baseline at week 4 (LOCF) and (c) patients achieving target blood pressure by dose group in the treat-to-target cohort.
Figure 3 Changes in mean (a) seated diastolic blood pressure (DBP) and (b) systolic blood pressurse (SBP) over the 52-week treatment period by group in the long-term cohort.
